Podium Abstract Presentation for the American Society of Colon and Rectal Surgeons 2010.
S.Buntzen,P.Lehur, S. McNevin, A. Mellgren, S. Laurberg, R. Madoff.
Purpose: Restoration of adequate sphincter function in case of end-stage fecal incontinence (FI) is still a challenge. We report our initial clinical results following implantation of a novel magnetic anal sphincter (MAS).
Read more on line (pg 24)
Click the image to donate online.
Providence Medical Research Center is located in The Fifth & Browne Medical Building (East Building).
Our mailing address is:
104 W 5th Ave. Suite 350 E
Spokane, WA 99204
Find maps and driving directions. Using the "Maps and Directions" link above, click on the mapquest icon to be sent to a pre-filled form with our address. Simply fill in your address for custom driving directions.
There are 26 million American adults with Chronic Kidney Disease (CKD). Often there are no symptoms with early kidney disease so most people aren't even aware that they have CKD. Millions of others are not aware that they are at risk. High risk groups include those with diabetes, hypertension and family history of kidney disease.
African Americans, Hispanics, Pacific Islanders, Native Americans and Seniors are also at increased risk. The key to preventing the progression of kidney disease is early detection.
The National Kidney Foundation's Kidney Early Evaluation Program (KEEP®) offers free screening for those with certain risk factors including anyone 18 years and older with high blood pressure, diabetes or a family history of kidney disease. KEEP is designed to raise awareness about kidney disease among high risk individuals and provide free testing and educational information so that kidney disease and its complications can be prevented or delayed.
There are three simple tests that can be done to detect CKD. These tests are: blood pressure check, a urine test for urine albumin (protein in the urine) and a blood test for serum creatinine (a blood protein byproduct).
To help raise awareness, and appreciation for all the vital functions the kidneys perform, the National Kidney Foundation is encouraging Americans to learn more and take steps now to preserve kidney health. March 12 is World Kidney Day, the perfect time to get to know your kidneys and find out if you're at risk.
To find out more Click Here
Advanced glycation end products (AGEs) are proinflammatory mediators implicated in the pathogenesis of diabetic kidney disease (DKD). In this study, dose-dependent effects of angiotensin receptor blockade on urinary AGEs were evaluated in patients with DKD. Patients with type 2 diabetes and proteinuria >=500 mg/d (n = 11) were compared with diabetic controls without DKD (n = 10) and normal controls (n = 11). After a 2-week washout period, DKD participants were treated with candesartan doses progressively increasing from 8, 16, 32, to 64 mg/d every 3 weeks for a total of 12 weeks. Other antihypertensive agents were adjusted to maintain stable blood pressure.
Katherine R. Tuttle , Am J Kidney Dis, 2009 Jan; 53(1): 12-15. (Commentary on the ACCORD Study Group: Effects of intensive Glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559, 2008 and the ADVANCE Collaborative Group: Intensive blood glucose control and vascular outcomes in patients with type 2 daibetes. N Engl J Med 358: 2560-2572, 2008 )
The effects of intensive glycemic control on cardiovascular disease (CVD) outcomes in "high risk" type 2 diabetes are the subject of much debate. The New England Journal of Medicine recently published results of two landmark clinical trials in patients with type 2 diabetes and CVD or multiple risk factors, ACCORD (Action to Control Cardiovascular Risk in Diabetes, n=10,521) and ADVANCE (Action in Diabetes and Cardiovascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation, n=11,140).1,2
- Options :
- View Article Map